KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares RepurchasedShort-Term Debt issuances
Ratios

Abbott Laboratories (ABT) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $13.3 billion.

  • Abbott Laboratories' Accumulated Depreciation & Amortization rose 879.37% to $13.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 billion, marking a year-over-year increase of 879.37%. This contributed to the annual value of $12.1 billion for FY2024, which is 257.24% up from last year.
  • Latest data reveals that Abbott Laboratories reported Accumulated Depreciation & Amortization of $13.3 billion as of Q3 2025, which was up 879.37% from $13.1 billion recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Accumulated Depreciation & Amortization registered a high of $13.3 billion during Q3 2025, and its lowest value of $9.9 billion during Q1 2021.
  • For the 5-year period, Abbott Laboratories' Accumulated Depreciation & Amortization averaged around $11.4 billion, with its median value being $11.5 billion (2023).
  • Per our database at Business Quant, Abbott Laboratories' Accumulated Depreciation & Amortization soared by 1358.65% in 2021 and then surged by 256.98% in 2022.
  • Quarter analysis of 5 years shows Abbott Laboratories' Accumulated Depreciation & Amortization stood at $10.4 billion in 2021, then increased by 6.2% to $11.0 billion in 2022, then rose by 6.6% to $11.8 billion in 2023, then grew by 2.57% to $12.1 billion in 2024, then grew by 10.18% to $13.3 billion in 2025.
  • Its Accumulated Depreciation & Amortization was $13.3 billion in Q3 2025, compared to $13.1 billion in Q2 2025 and $12.5 billion in Q1 2025.